Article
Efficient Correction of Oncogenic KRAS and TP53 Mutations through CRISPR Base Editing.
Cancer research - 2 Sept 2022
Sayed Shady, Sidorova Olga A, Hennig Alexander, Augsburg Martina, Cortés Vesga Catherine P, Abohawya Moustafa, Schmitt Lukas T, Sürün Duran, Stange Daniel E, Mircetic Jovan, Buchholz Frank
Abstract excerpt
KRAS is the most frequently mutated oncogene in human cancer, and its activating mutations represent long-sought therapeutic targets. Programmable nucleases, particularly the CRISPR-Cas9 system, provide an attractive tool for genetically targeting KRAS mutations in cancer cells. Here, we show that cleavage of a panel of KRAS driver mutations suppresses growth in various human cancer cell lines, revealing their...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.